Fragment-Based Drug Discovery, Punta Cana. IntelliSyn will be presenting recent results in a presentation entitled: “Extending the range of fragment methodologies: Applications in the absence of crystallography”.
June 23-25. Bio-2014, San Diego, California
Mastering Medicinal Chemistry, Boston, Massachusetts. IntelliSyn will present on the following: “Development of highly potent, selective BET bromodomain inhibitors that are CNS penetrant and effective in rodent models of brain cancer.”
Drug Discovery Chemistry Conference San Diego. We will be presenting our developments in the discovery of CNS penetrant bromodomain inhibitors for GBM and metastatic brain cancer.
April 1, 2014 – IntelliSyn successfully reaches its milestone with Epigenetix and partners its BRD4 inhibitor project with the NeoMed Institute to advance to clinical trials. http://www.neomed.ca/images/pdf/NEOMED_Epigenetix_April1_En.pdf